Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 2nd November 2017
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

APHA awarded $100,000 to develop brucellosis vaccine
Wholesale vaccination of livestock can be a cost-effective way of controlling brucellosis.
Vaccine to deliver lasting benefits to human and animal health

The Animal and Plant Health Agency (APHA) has been awarded $100,000 in the AgResults’ Brucellosis Vaccine Prize competition. The money will be used to develop a vaccine that is effective for use against small ruminants across the developing world.

The APHA received the funding for Phase 1 of the vaccine development and was awarded based on the agency's scientific soundness, suitable research and appropriate manufacturing capabilities.

Dr John McGiven, who is leading the project, said: “We feel the AgResults competition elevates recognition of the significance of this insidious and debilitating disease. For many years we have been focusing on improved methods for the serodiagnosis of brucellosis and this research revealed to us a route towards a new type of vaccine against brucellosis.

“This competition gave us additional incentive to pull these innovative concepts together in the belief that we can make a big difference to brucellosis control.”

Brucellosis is a devastating disease that leads to infertility, abortions and decreased milk production. It affects many animals, including small ruminants and is endemic in a number of developing countries.

Wholesale vaccination of livestock can be a cost-effective way of controlling the disease and reducing its impact on human and animal health. However, existing vaccines are unsafe for use in pregnant animals, have variable efficacy, and can harm humans.

The Brucellosis Vaccine Prize Competition, managed by AgResults, has three phases and may run for 10 years. $30 million is available to entrants, with three milestone payments at different stages.

Dr McGiven’s team is now working on Phase 2 of the vaccine development, by developing a proof of concept vaccine that meets efficacy and safety requirements. It is hoped the vaccine will deliver lasting benefits to human and animal health.

Become a member or log in to add this story to your CPD history

Submissions open for BSAVA Clinical Research Abstracts 2026

News Story 1
 The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.

It is an opportunity for applicants to present new research on any veterinary subject, such as the preliminary results of a study, discussion of a new technique or a description of an interesting case.

They must be based on high-quality clinical research conducted in industry, practice or academia, and summarised in 250 words.

Applications are welcome from vets, vet nurses, practice managers, and students.

Submissions are open until 6 March 2026. 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk